Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Protective Effects of Liraglutide Against Risperidone Induced Metabolic Dysfunction in Adolescent Mice

FY 2023-24

Summary
Atypical antipsychotics (AAP) are the standard treatment for children suffering from a mental illness or psychiatric disorder, with risperidone (RS) being one of the most commonly prescribed. RS treatment is not without risk & side effects include weight gain and other severe metabolic perturbations that increase the child's risk of developing cardiovascular disease as an adult. Not all pharmacological co-treatments have been efficacious at mitigating these side effects, though a promising area of research involves a class of drugs known as glucagon-like peptide (GLP)1 agonists due to their ability to decrease body weight and improve glucose homeostasis. Notably, liraglutide (LG) has demonstrated great potential as it was able to mitigate AAP-induced metabolic dysfunction in adults with schizophrenia without compromising psychiatric treatment. However, RS and LG co-treatment has yet to be investigated in a pediatric model. Our aim is to answer the question of whether LG co-treatment can attenuate the RS-induced metabolic perturbations in a pediatric mouse model. We will also be investigating the negative side effects of LG treatment in regards to lean mass and whether there are differences in outcome based on sex. 8 groups of adolescent mice (male or female control, RS, RS+LG, LG) will be treated for 5 weeks. We will take a series of measurements throughout to obtain a comprehensive analysis of metabolic function including, but not limited to, energy expenditure, body weight, glucose tolerance, individual muscle weights, liver lipid content, and adipocyte size. Our findings could provide important insight into approaches to treat the metabolic complications of RS in children while highlighting the existence of potential negative side effects that should be considered.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
506221
Name
Trang Serena
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Protective Effects of Liraglutide Against Risperidone Induced Metabolic Dysfunction in Adolescent Mice
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Antipsychotic Drugs; Diabetes; Drug Metabolism; Energy Metabolism; Glucose Metabolism; Mental Health; Metabolic Diseases; Metabolic Syndrome; Obesity; Pediatric Obesity
Abstract
Atypical antipsychotics (AAP) are the standard treatment for children suffering from a mental illness or psychiatric disorder, with risperidone (RS) being one of the most commonly prescribed. RS treatment is not without risk & side effects include weight gain and other severe metabolic perturbations that increase the child's risk of developing cardiovascular disease as an adult. Not all pharmacological co-treatments have been efficacious at mitigating these side effects, though a promising area of research involves a class of drugs known as glucagon-like peptide (GLP)1 agonists due to their ability to decrease body weight and improve glucose homeostasis. Notably, liraglutide (LG) has demonstrated great potential as it was able to mitigate AAP-induced metabolic dysfunction in adults with schizophrenia without compromising psychiatric treatment. However, RS and LG co-treatment has yet to be investigated in a pediatric model. Our aim is to answer the question of whether LG co-treatment can attenuate the RS-induced metabolic perturbations in a pediatric mouse model. We will also be investigating the negative side effects of LG treatment in regards to lean mass and whether there are differences in outcome based on sex. 8 groups of adolescent mice (male or female control, RS, RS+LG, LG) will be treated for 5 weeks. We will take a series of measurements throughout to obtain a comprehensive analysis of metabolic function including, but not limited to, energy expenditure, body weight, glucose tolerance, individual muscle weights, liver lipid content, and adipocyte size. Our findings could provide important insight into approaches to treat the metabolic complications of RS in children while highlighting the existence of potential negative side effects that should be considered.
Competitiondate
202312
Approvedterm2
1 yr 0 mth
Pinamesdelim
Trang, Serena
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~